Puma Biotechnology Inc - Company Profile
Powered by
All the data and insights you need on Puma Biotechnology Inc in one report.
- Save hours of research time and resources with
our up-to-date Puma Biotechnology Inc Strategy Report
- Understand Puma Biotechnology Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Puma Biotechnology Inc (Puma) is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer. The company develops and commercializes drug candidates, namely, PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. The company’s pipeline portfolio also encompasses investigational candidates for various indications such as adjuvant breast cancer, gastric cancer, metastatic breast cancer and HER2-positive breast cancer and other cancers. Puma in-licenses its drug candidates and advances its development through clinical testing and for commercial use. Puma manufacture and distribute its products through the third party contractors. Puma is headquartered in Los Angeles, California, the US.
Puma Biotechnology Inc premium industry data and analytics
Products and Services
Products |
---|
Product: |
Neratinib - Early Stage HER2-Overexpressed/Amplified Breast Cancer, HER2-Positive |
Pipeline Portfolio: |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Puma Biotechnology Inc | F. Hoffmann-La Roche Ltd | Novartis AG | Takeda Pharmaceutical Co Ltd | Boehringer Ingelheim International GmbH |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | Switzerland | Japan | Germany |
City | Los Angeles | Basel | Basel | Chuo-Ku | Ingelheim am Rhein |
State/Province | California | - | - | Tokyo | Rheinland-Pfalz |
No. of Employees | 185 | 103,605 | 76,057 | 49,095 | 53,000 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Alan H. Auerbach | Chairman; Chief Executive Officer; President | Executive Board | 2011 | 53 |
Maximo F. Nougues | Chief Financial Officer | Senior Management | 2018 | 54 |
Alvin Wong | Chief Scientific Officer | Senior Management | 2021 | 70 |
Jeff J. Ludwig | Chief Commercial Officer | Senior Management | 2020 | 57 |
Douglas Hunt | Senior Vice President - Regulatory Affairs, Medical Writing and Project Management | Senior Management | 2018 | 58 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward